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Abstract: The aim of this multi-center, open-label, randomized, parallel-group trial was to 
compare the efﬁ  cacy of rosuvastatin with that of simvastatin in achieving the 1998 European 
Atherosclerosis Society (EAS) lipid treatment goals. 504 patients (18 years) with primary 
hypercholesterolemia and a 10-year cardiovascular (CV) risk 20% or history of coronary heart 
disease (CHD) or other established atherosclerotic disease were randomized in a 2:1 ratio to 
receive rosuvastatin 10 mg or simvastatin 20 mg once daily for 12 weeks. A signiﬁ  cantly higher 
proportion of patients achieved 1998 EAS low-density lipoprotein cholesterol (LDL-C) goal after 
12 weeks of treatment with rosuvastatin 10 mg compared to simvastatin 20 mg (64 vs 51.5%, 
p  0.01). Similarly, signiﬁ  cantly more patients achieved the 1998 EAS total cholesterol (TC) 
goal and the 2003 EAS LDL-C and TC goals (p  0.001) with rosuvastatin 10 mg compared 
with simvastatin 20 mg. The incidence of adverse events and the proportion of patients who 
discontinued study treatment were similar between treatment groups. In conclusion, in the 
DISCOVERY-Beta Study in patients with primary hypercholesterolemia greater proportion of 
patients in the rosuvastatin 10 mg group achieved the EAS LDL-C treatment goal compared with 
the simvastatin 20 mg group. Drug tolerability was similar across both treatment groups.
Keywords: hypercholesterolemia, low-density lipoprotein cholesterol, statins, rosuvastatin, 
simvastatin, tolerability
Introduction
Despite a substantial decrease in cardiovascular disease (CVD) mortality over the past 
30 years in several industrialized countries, coronary heart disease (CHD) remains the 
leading cause of morbidity and mortality (Thom 1989; Tunstall-Pedoe et al 2003). The 
decline in CHD mortality has been accompanied by a simultaneous decrease in the 
main risk factors. This has led to speculation that during the 1970s the decline in CHD 
mortality rate was mainly due to primary prevention, but during the 1980s improved 
treatment and secondary prevention have increasingly contributed to the decrease 
(Vartiainen et al 1994). At the same time, in most developing countries, the incidence 
of CVD is increasing towards epidemic levels (Reddy and Yusuf 1998). Also, in Eastern 
Europe CHD morbidity and mortality rates, particularly among men, are high compared 
with other areas of Europe (Sans et al 1997). Estonia, an eastern European country 
and formerly part of the former Soviet Union, has been facing high CVD and CHD 
rates. In Estonia, CVD and CHD account, respectively, for 55% and 32% of all deaths 
(Estonian Medical Statistical Buerau 1997; Laks et al 1999). The age-standardized 
mortality rates by the World Health Organization multinational MONItoring of trends 
and determinants in CArdiovascular disease (WHO MONICA) Project protocol criteria Vascular Health and Risk Management 2008:4(6) 1408
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for 35- to 64-year-old people per 100,000 population in 
Estonia ranged from 208 to 317 for men and from 31 to 61 
for women, substantially higher than rates in southern and 
central European centers of the WHO MONICA Project 
(Laks et al 1999; Tunstall-Pedoe et al 1999).
Findings that an excess of total cholesterol (TC) and 
low-density lipoprotein cholesterol (LDL-C) particles are the 
main causes of atherosclerosis and major risk factors for CHD 
have been conﬁ  rmed by molecular biology, animal experi-
ments, and clinical and epidemiological trials (LaRosa et al 
1990; Vartiainen et al 1994; Levine et al 1995; Coresh et al 
1996). The importance of elevated TC and LDL-C levels are 
described in many guidelines (Wood et al 1998; Adult Treat-
ment Panel III 2001; De Backer et al 2003). Substantial low-
ering of LDL-C level has been associated with risk reduction 
and a reduction in CHD events (de Lorgeril et al 1999; Ito 
et al 2001). Despite the introduced guidelines and the avail-
ability of lipid-lowering therapies (LLT), many patients fail 
to meet TC and LDL-C goals (Pearson et al 2000). Results 
from large-scale trials have conﬁ  rmed the effectiveness of 
the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors (statins) in the primary and secondary 
prevention on CHD. However, the residual morbidity and 
mortality remains high (Gotto and Grundy 1999). Therefore, 
the development of more effective lipid-lowering drugs has 
potential to further improve CV risk reduction.
The DIrect Statin COmparison of LDL-C Values: an 
Evaluation of Rosuvastatin therapY (DISCOVERY) Study 
was series of 9 independently powered studies performed 
in different countries and regions worldwide, includ-
ing: The Netherlands (Bots and Kastelein 2005); Triple 
Country – Iceland, Ireland, Finland (Strandberg et al 2004); 
Asia (Zhu et al 2007); Alpha – Eastern Europe, Central 
and South Africa, the Middle East (Binbrek et al 2006); 
Belux – Belgium, Luxembourg (Herregods et al 2006); 
Canada (Gupta and Constance 2005); Penta – Latin America, 
Portugal (Fonseca et al 2005); Beta (Estonia); and the United 
Kingdom (Middleton and Fuat 2006). These studies aimed 
to compare the efﬁ  cacy of rosuvastatin 10 mg with that of 
other statins (given at their respective recommended starting 
doses) in achieving recommended lipid levels in the clinical 
setting. Simvastatin 20 mg was chosen as the comparator, 
because it was the standard of care in Estonia at the time 
of the start of the study. The DISCOVERY study program 
started in March 2002. The primary objective of this trial 
was to provide the results for the DISCOVERY-Beta Study, 
which compared the efﬁ  cacy of rosuvastatin 10 mg with 
that of simvastatin 20 mg to achieve the 1998 European 
Atherosclerosis Society (EAS) LDL-C treatment goal (Wood 
et al 1998). The 1998 EAS LDL-C goal served as primary 
endpoint in the Discovery series studies, making it possible 
to use the data for the meta-analysis of the series.
Methods
Trial design and patients
The DISCOVERY-Beta was a 12-week multi-center, open-
label, randomized, parallel-group study conducted between 
March and September 2004 at 18 centers in Estonia. Men 
and women (aged 18 years) were enrolled with primary 
hypercholesterolemia (LDL-C  3.5 mmol/L if statin-naïve 
or 3.1 mmol/L if switching) and a 10-year CV risk 20% 
or a history of CHD or other established atherosclerotic dis-
ease (cerebrovascular disease as transient ischemic attack, 
ischemic stroke, or carotid artery disease; CHD as acute 
myocardial infarction [AMI], unstable angina, or coronary 
revascularization; peripheral arterial disease [PAD] as aortic 
aneurysm, intermittent claudication, lower limb arterial 
revascularization, or amputation due to the complications of 
atherosclerosis) and fasting triglycerides (TG) 4.52 mmol/L 
at visit 2 (week 0). Subjects were selected by cardiologists, 
internists, and general practitioners (when needed if previ-
ously consulted by cardiologist) from a primary or secondary 
prevention subject population. Statin-naïve subjects (those 
who had not received a statin within the previous 6 months) 
or subjects on a start dose (commonly used or accepted 
starting doses were atorvastatin 10 mg, ﬂ  uvastatin 20 mg, 
or pravastatin 20 mg) or other LLT, which was ineffec-
tive (ie, subjects had not reached their LDL-C goal at that 
dose), were entered into this study. Dietary counseling for 
6 weeks was given for statin-naïve patients before enrolling 
into the study. Main exclusion criteria were: known familial 
hypercholesterolemia; secondary dyslipidemia of any cause; 
history of serious adverse effect (SAE) or hypersensitivity 
to other HMG-CoA reductase inhibitors; pregnancy, breast-
feeding, and women of childbearing potential not using 
chemical or mechanical contraception or with a positive 
pregnancy test; malignancy; use of disallowed concomitant 
medications (antibiotics clarithromycin or erythromycin, 
antifungal treatment with ﬂ  uconazole, ketoconazole, or 
itraconazole, lipid-lowering agents, cyclosporin); history of 
alcohol or drug dependence; active liver disease or hepatic 
dysfunction with elevations of alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) 1.5 times 
upper limit of normal (ULN); renal impairment as deﬁ  ned 
by serum creatinine 220 μmol/L (2.5 mg/dL); uncontrolled 
diabetes; unstable angina; uncontrolled hypertension as either Vascular Health and Risk Management 2008:4(6) 1409
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diastolic 95 mmHg or systolic blood pressure 200 mmHg; 
unexplained serum creatine kinase (CK) 3 times ULN; 
subjects in serious or unstable medical or psychological 
condition that compromises the subject safety or participa-
tion in the trial. Investigators of each center ensured that 
each patient gave written informed consent for participation 
in the study.
Patients were assessed for eligibility and, within 2 weeks, 
were randomized in a 2:1 ratio to receive rosuvastatin 10 mg 
or simvastatin 20 mg administered once daily for 12 weeks. 
Patients were allocated numbers as they entered the study, 
and a computer-generated randomization scheme was used 
to determine treatment allocation as each patient became 
eligible. Treatment codes for each patient were provided 
to each center in a sealed envelope, and investigators were 
unaware of the randomization scheme and treatment codes 
until the envelope was opened at the randomization visit.
Efﬁ  cacy and tolerability assessments
At each visit (screening at week –2, randomization at week 0, 
ﬁ  nal at week 12) blood samples were drawn to determine 
serum levels of TC, LDL-C, high-density lipoprotein cho-
lesterol (HDL-C), and TG. Local laboratories were used in 
the study. Serum LDL-C level was determined using the 
Friedewald formula (Friedewald et al 1972). Patients with 
TG  4.52 mmol/L were excluded from the study, so that the 
confounding effect of elevated TG level on the Friedewald 
formula was minimized.
The primary endpoint was the percentage of patients 
achieving the 1998 EAS LDL-C goal (3.0 mmol/L) at week 
12. Secondary efﬁ  cacy endpoints included: 1. percentage of 
patients achieving the 1998 EAS TC goal (5.0 mmol/L); 
2. percentage change from pre-dose and ﬁ  nal visit in serum 
LDL-C, TC, HDL-C, and TG levels in statin-naïve and 
switched patients; 3. comparing the efﬁ  cacy of rosuvastatin 
10 mg with simvastatin 20 mg by assessment of percentage 
of subjects who reach the 2003 EAS LDL-C (2.5 mmol/L) 
or TC (4.5 mmol/L) target goals for patients with clini-
cally established CVD and/or diabetes mellitus (DM) after 
12 weeks of therapy; 4. comparison of rosuvastatin 10 mg 
with simvastatin 20 mg after 12 weeks of treatment for the 
incidence and severity of adverse events (AEs) and abnormal 
laboratory values. Lipid levels were determined from fasting 
(12 hours) blood samples analyzed in local laboratories. The 
incidence and severity of AEs, including abnormal labora-
tory values (liver enzymes, creatinine, CK) were recorded 
to assess tolerability. At every visit, AEs were reported 
to investigators in response to a standard questionnaire. 
Any decline in a patient’s condition subsequent to study 
entry was considered an AE. Also, the relationship of SAEs 
to the treatment was assessed.
Statistical analysis
The trial has been sized to detect a difference of 15% between 
rosuvastatin 10 mg and simvastatin 20 mg, in terms of the 
percentage of subjects reaching the 1998 EAS LDL-C target 
goal at week 12. Using these data, and the fact that patients 
were randomized in a 2:1 ratio (rosuvastatin : simvastatin), 
it was calculated that 480 evaluable subjects were required 
to achieve 90% power for a two-sided signiﬁ  cance level of 
5%. Subjects were evaluated based on an intention to treat 
(ITT) population which consisted of subjects who had a 
baseline reading, one week 12 reading, and at least one dose 
of medication. If a subject was withdrawn prior to week 12, 
the last value after baseline was taken as the week 12 assess-
ment. The numbers of subjects reaching the 1998 EAS lipid 
target goals on rosuvastatin 10 mg and simvastatin 20 mg at 
week 12 were compared using a logistic regression analysis 
with factors being ﬁ  tted for treatment, subject type (naïve 
or switched) and the pre-dose lipid parameter value ﬁ  tted 
as a covariate. For lipid parameters, analyses of percentage 
change for pre-dose (week 0) and at week 12 were performed 
separately for the naïve and switched patients because the 
week 0 value for statin-naïve patients followed 6 weeks 
of dietary advice, whereas this was not case for switched 
patients. The analyses were performed using the ANCOVA 
model, with factors ﬁ  tted for treatment and the pre-dose 
(week 0) lipid parameter value as a covariate. The results 
are presented as least squares means (LSM) and the differ-
ence between the LSM, with p values and associated 95% 
conﬁ  dence intervals. In addition, the percentage change in 
lipid parameters has been summarized.
Results
Patient characteristics
Of 586 patients screened, 504 (59.3 % women and 40.7% 
men) were randomized at visit 2 (week 0) into the treatment 
groups (rosuvastatin 10 mg 334 and simvastatin 20 mg 
170 patients) and received at least 1 dose of the study drug, 
and had baseline and week 12 lipid measurements available 
(ITT population). Eighty-two patients were discontinued 
before randomization: in 73 subjects eligibility criteria were 
not fulﬁ  lled, 1 subject ALT was elevated 3 times ULN, and 
8 subjects withdrew their consent (Figure 1) .
Baseline demographic, clinical characteristics, risk 
factors, and previous LLT for 504 randomized patients are Vascular Health and Risk Management 2008:4(6) 1410
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presented in Table 1. Sex distribution, clinical characteristics 
of study subjects, and frequency of risk factors (body mass 
index [BMI], systolic and diastolic blood pressure [BP], 
documented atherosclerotic disease, type 2 DM, family 
history of premature CHD and PAD, smoking, low HDL or 
elevated TG) were similar between the two treatment groups. 
In total, 187 (37.1%) patients had documented atherosclerotic 
disease, 115 (22.8%) type 2 DM, 98 (19.4%) family history of 
premature CHD or PAD, 25 (5.0%) low HDL, 208 (41.3%) 
elevated TG, and 167 (33.1%) were smokers. 119 (23.6%) 
of the total study population had previously received LLT, 
82 patients (24.6%) in the rosuvastatin group compared 
with 37 (21.8%) patients in the simvastatin group. The most 
frequently prescribed LLTs were pravastatin (60 patients, 
11.9%) and atorvastatin (29 patients, 5.8%).
Efﬁ  cacy
The proportions of patients reaching the 1998 EAS LDL-C 
goal (primary endpoint), the 1998 and 2003 EAS TC, and 
the 2003 EAS LDL-C goals (all secondary endpoints) after 
12 weeks of treatment with either rosuvastatin 10 mg or 
simvastatin 20 mg are presented in Table 2. Signiﬁ  cantly 
more patients in the rosuvastatin group achieved the 1998 
EAS LDL-C goal compared with those in the simvastatin 
group, 210 (64%) and 86 (51.5%) patients (p  0.01). In 
addition, signiﬁ  cantly more statin-naïve subjects achieved 
the goal in the rosuvastatin arm compared with simvastatin, 
165 (67.1%) versus 71 (54.6%) patients (p  0.001). The 
same trend occurred within switched patients 45 (54.9%) 
patients in the rosuvastatin group compared to 15 (40.5%) 
patients in the simvastatin group. A signiﬁ  cantly higher 
Enrolled 
n = 586 
Discontinued N = 82 
Eligibility criteria not fulfilled 
(n = 73) 
Withdrawal of consent (n = 8) 
ALT or AST >3 × ULN (n = 1) 
Randomized 
n = 504 
Rosuvastatin 
n = 334 
Simvastatin 
n = 170 
Discontinued n = 30 
AE (n = 24) 
Non-compliance with the 
protocol (n = 3) 
Screening failure (n = 3) 
Discontinued n = 14 
Withdrawal of consent (n = 1) 
AE (n = 7) 
Non-compliance with the 
protocol (n = 3) 
Screening failure (n = 3) 
Completed study
n = 304 
Completed study
n = 156 
Figure 1 Patient disposition in study groups.
Abbreviations: AE, adverse event;   ALT, alanine aminotransferase;   AST, aspartate aminotransferase; ULN, upper limit of normal.Vascular Health and Risk Management 2008:4(6) 1411
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Table 1 Baseline demographic and clinical characteristics of the study population was statistically not different in the two treatment groups
Characteristic Rosuvastatin (n = 334) Simvastatin (n = 170)
Age, y (SD) 62.9 (9.4) 63.9 (9.7)
Sex, no (%)
  Female 200 (59.9) 99 (58.2)
  Male 134 (40.1) 71 (41.8)
BMI, kg/m² (SD) 29.6 (4.7) 28.8 (4.7)
BP, mmHg (SD)
  Systolic 147.6 (19.2) 148.4 (19.6)
  Diastolic 84.7 (8.5) 84.3 (8.0)
Risk factors, no. (%)
 Atherosclerosisa 122 (36.5) 65 (38.2)
  Type 2 DM 79 (23.7) 36 (21.2)
  Family history of
  premature CHD or PADa 64 (19.2) 34 (20.0)
  Current smoking 112 (33.5) 55 (32.4)
  Low HDL (0.9 mmol/L) 16 (4.8) 9 (5.3)
 Elevated  TG  (2.0 mmol/L) 139 (41.6) 69 (40.6)
Switched from previous LLT, no. (%) 82 (24.6) 37 (21.8)
  Rosuvastatin 1 (0.3) 0 (0)
  Simvastatin 15 (4.5) 8 (4.7)
  Atorvastatin 18 (5.4) 11 (6.5)
  Pravastatin 43 (12.9) 17 (10.0)
Other LLT (ﬁ  brates) 5 (1.5) 1 (0.6)
aDeﬁ  ned as
1) Patients with a history of transient ischemic attacks (TIA) or ischemic stroke, carotid artery disease as evidenced by a history carotid endarterectomy, angioplasty, or other 
cerebral revascularization. Patients with advanced (at least 60% stenosis) atherosclerosis in the common or internal carotid artery documented (by angiography or ultrasound) 
will also be eligible.
2) Patients with coronary artery disease, deﬁ  ned by a history of myocardial infarction or hospitalization for treatment of unstable angina, angina pectoris corroborated by 
objective evidence of myocardial ischemia, coronary revascularization or angiographic evidence of stenosis 50% in one or more major epicardial coronary artery.
3) Patients with peripheral arterial disease deﬁ  ned by a history of aortic aneurysm repair, aorto-iliac, femoral or other arterial surgery or angioplasty performed to relieve 
lower limb ischemia, lower limb amputation performed due to complications of atherosclerotic arterial disease, or, intermittent claudication with an ankle-brachial pressure 
index (ABI) 0.9.
Abbreviations: CHD, coronary heart disease; HDL, high density lipoprotein; LLT, lipid-lowering therapies; PAD, peripheral arterial disease; TG, fasting triglycerides.
Table 2 Subjects (%) reaching the 1998 and the 2003 EAS lipid (mmol/L) target goals at the end of the study (week 12)
Target LDL-C and TC Rosuvastatin 
n = 328
Simvastatin 
n = 167
1998 EAS LDL-C  3.0 210 (64.0) 86 (51.5) p  0.01
1998 EAS TC  5.0 195 (59.5) 72 (43.1) p  0.001
2003 EAS LDL-C  3.0 or  2.5
with established CVD or DM 146 (44.5) 37 (22.2) p  0.001
2003 EAS TC  5.0 or  4.5
with established CVD or DM 141 (43.0) 43 (25.7) p  0.001
Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus; EAS, european atherosclerosis society; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.
number of patients in the rosuvastatin group achieved the 
1998 EAS TC goal compared with patients in simvastatin 
arm, 195 (59.5%) versus 72 (43.1%) patients (p  0.001). 
This analysis was made within the total ITT population, as 
there was no signiﬁ  cant difference between statin-naïve and 
switched subjects. Similarly, a signiﬁ  cantly greater number of 
patients receiving rosuvastatin 10 mg reached the 2003 EAS 
LDL-C and TC goals compared with patients in the simvas-
tatin group, 146 (44.5%) and 37 (22.2%) patients (p  0.001) 
and 141 (43%) and 43 (25.7%) patients (p  0.001).Vascular Health and Risk Management 2008:4(6) 1412
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Percentage change from baseline levels of LDL-C, TC, 
HDL-C, and TG in both statin-naïve and switched patients 
are shown in Table 3.
In both treatment groups, in statin-naïve and switched 
subjects, TG levels declined from baseline, but these 
decreases were too small to be signiﬁ  cant. At the same time, 
during the 12-week treatment period there were no changes 
in HDL-C levels in statin-naïve patients in the rosuvastatin 
and simvastatin groups, and changes in switched patients 
were small.
Safety
The occurrence of AEs was similar between groups. Both 
study statin treatments (rosuvastatin and simvastatin) were 
generally well tolerated, and the incidence of AEs and SAEs 
was low. The proportion of patients who discontinued study 
treatment because of AEs did not differ statistically – in the 
rosuvastatin group 7.2% and in the simvastatin group 4.1% 
(Table 4). The most common AEs leading to withdrawal from 
the study were gastrointestinal disorders such as abdominal 
pain and nausea, and the musculoskeletal disorder myalgia. 
SAEs were reported by 1.8% of study subjects. The only 
death (due to AMI) during the trial was in the rosuvastatin 
group, and was considered by the investigator to have 
been unrelated to the investigational product. All SAEs 
were judged by the investigators as having had no causal 
relationship to the study treatment, with the one exception 
of general discomfort (not related to myalgia) reported 
by a patient receiving simvastatin. The most common AE 
was nausea, in 13 patients (3.9%) in the rosuvastatin group 
and in 6 patients (3.5%) in simvastatin group. Myalgia, a 
known side effect of statin therapy, had a statistically not 
signiﬁ  cant tendency to be reported more frequently with 
rosuvastatin – by 10 patients (3%) compared with 1 patient 
(0.6%) in simvastatin group. None of these reports were 
associated with a clinically signiﬁ  cant increase in CK (10 
times ULN). Rhabdomyolysis occurred in none of the 
patients. Mean changes from baseline in circulating levels of 
ALT, CK, and creatinine at week 12 were small and similar 
between the rosuvastatin and simvastatin groups, and gener-
ally unremarkable. Only 1 patient from each group had a CK 
level at week 12 of special note (3 times ULN).
Subjects with multiple AEs in the same category are 
counted only once in that category; subjects with AEs  1 
category are counted once in each category.
Discussion
CVD is major health problem and a leading cause of global 
mortality (Thom 1989; Sans et al 1997; Reddy and Yusuf 
1998; Tunstall-Pedoe et al 2003). Despite the decline in 
CHD mortality during recent decades in most Western 
countries, it remains high because of the aging population 
Table 3 Changes in lipid proﬁ  les before and after 12 weeks treatment with rosuvastatin 10 mg and simvastatin 20 mg
Rosuvastatin n = 334 Simvastatin n = 170
Baseline 12 weeks %Δ Baseline 12 weeks %Δ
Mean LSM Mean Mean Mean LSM
Lipid n mmol/L mmol/L (SE) n mmol/L mmol/L (SE) p valuea
LDL-C Total 334 4.73 2.83 −38.79 (1.27) 170 4.66 3.12 −32.03 (1.37) 0.001
 Statin-naïve 252 4.87 2.72 −42.94 (0.001) 133 4.73 3.09 −34.20 (0.01) 0.0001
 Switched 82 4.27 3.06 −26.39 (0.03) 37 4.39 3.21 −24.42 (0.03)  NS
TC Total 334 7.13 4.89 −30.41 (0.88) 170 7.00 5.18 −25.27 (1.09) 0.01
 Statin-naïve 252 7.33 4.83 –33.42  (0.01) 133 7.07 5.13 −27.08 (0.01) 0.0001
 Switched 82 6.51 5.06 −21.40 (0.02) 37 6.76 5.36 −18.91 (0.02)  NS
HDL-C Total 334 1.46 1.45 +0.66 (1.14) 170 1.41 1.43 +2.26 (1.47) NS
 Statin-naïve 252 1.47 1.47 +0.01 (0.01) 133 1.40 1.40 +0.02 (0.02) NS
 Switched 82 1.39 1.34 –0.01  (0.02) 37 1.43 1.47 +0.03 (0.03) NS
TG Total 334 1.90 1.51 −14.47 (1.86) 170 1.92 1.61 −14.43 (2.45) NS
 Statin-naïve 252 1.92 1.50 −14.83 (0.02) 133 1.88 1.50 −16.82 (0.03) NS
 Switched 82 1.87 1.53 −13.39 (0.02) 37 2.06 1.92 −6.03 (0.06) NS
ap, rosuvastatin vs simvastatin.
Abbreviations: LSM, least squares means; SE, standard error; LDL-C, low-density lipoprotein cholesterol;  HDL-C, high-density lipoprotein cholesterol TC, total cholesterol; 
TG, fasting triglycerides.Vascular Health and Risk Management 2008:4(6) 1413
Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients
(Sleight 2003). CVD includes CHD, and is most frequently 
caused by atherosclerosis, a progressive condition that may 
remain asymptomatic for many years, with sudden death 
often being the ﬁ  rst clinical manifestation (Thaulow et al 
1993). Elevated LDL-C is an important contributory factor 
to development of atherosclerosis, and as such is recognized 
as a major risk factor for CHD. Consequently, LDL-C is a 
key therapeutic target for the prevention of CHD, with statins 
recommended as ﬁ  rst-line drug treatment (Adult Treatment 
Panel III 2001; De Backer et al 2003).
This randomized, multi-center study comparing lipid-
modifying efﬁ  cacy of two statins showed that on the basis 
of both the 1998 EAS and the stricter 2003 EAS LDL-C 
goals, rosuvastatin showed greater efﬁ  cacy in reducing 
LDL-C compared with simvastatin with commonly used 
starting doses (rosuvastatin 10 mg and simvastatin 20 mg 
once a day) over 12 weeks of treatment in patients with 
primary hypercholesterolemia. Also, up to the end of the 
study, more hypercholesterolemic patients in the rosuvas-
tatin group achieved a reduction in TC levels to the EAS 
target goals (Wood et al 1998; De Backer 2003) compared 
with simvastatin-treated patients. Our study conﬁ  rms the 
results of previous trials comparing the efﬁ  cacy of differ-
ent statins, that rosuvastatin, at a commonly used starting 
dose, is highly effective in reducing LDL-C levels. Thus, 
in the DISCOVERY-Beta Study as in the earlier published 
MERCURY I (Schuster et al 2004), STELLAR (Jones et al 
2003), and Rosuvastatin Study Group trials (Brown et al 
2002), rosuvastatin was more effective than other statins 
used (atorvastatin, simvastatin, pravastatin) in decreasing 
LDL-C levels and allowing more patients to achieve the 
recommended treatment goals. This effect was evident 
from week 6 and continued to at least week 52 during 
the LLT.
The DISCOVERY-Beta Study randomized a large 
proportion of patients (24%) who had not reached the EAS 
lipid goals with LLTs. At the same time the reduction of 
LDL-C in statin-naïve patients with rosuvastatin 10 mg was 
signiﬁ  cantly higher than with simvastatin 20 mg (43% and 
34%, respectively).
HDL-C has taken on increased importance as a clinical 
prognostic factor for CVD, which is reﬂ  ected in coronary 
preventive guidelines (Wood et al 1998; Adult Treatment 
Panel III 2001; De Backer et al 2003). In our study analysis 
of the data from the ﬁ  xed-dose treatment period, comparing 
rosuvastatin 10 mg with simvastatin 20 mg did not reveal 
any changes in HDL-C levels in both groups during the 
12 weeks. The reasons could be the relatively high baseline 
values for HDL-C in both groups and/or some technical 
issues caused by the fact that local laboratories instead of 
one central laboratory were used for sample analysis. No 
deﬁ  nitive or primary reference methods exist for the sepa-
ration of HDL, and because differences in the precipitation 
procedures can alter the population of particles precipitated, 
not all methods give the same result for HDL cholesterol, and 
therefore standardization of HDL cholesterol measurement 
is difﬁ  cult (Marques-Vidal et al 1999). However, questions 
remain as to the speciﬁ  city of these assays under contrasting 
conditions of high and low LDL levels as typically observed 
in statin trials.
In our study rosuvastatin 10 mg was as effective as 
simvastatin 20 mg at reducing TG in both statin-naïve and 
switched patients, conﬁ  rming results obtained with rosuvas-
tatin 10 mg in earlier published reports (Brown et al 2002; 
Davidson et al 2002; Jones et al 2003; Binbrek et al 2006). 
In the DISCOVERY-Beta Study, both rosuvastatin 10 mg 
and simvastatin 20 mg were well tolerated, with similar 
proﬁ  les of AEs reported with both agents. There appeared to 
be no differences between treatment groups. The types and 
numbers of AEs and overall safety proﬁ  le were consistent 
with those reported for statin therapy (Knopp 1999; Schuster 
2003). However, in our study we found no reports of myopa-
thy or rhabdomyolysis, and rate of myalgia was low in both 
groups. Treatment discontinuation was similar in both arms 
of the study; however, in the rosuvastatin group there were 
4 cases of AMI which were deemed by the investigators to 
be unrelated to the investigated product. Signiﬁ  cant elevation 
in liver enzymes was similarly rare in both groups in both 
treatment populations.
Table 4 Adverse events in rosuvastatin and simvastatin treatment 
groups (%)
Category of AEs Rosuvastatin 
n = 334
Simvastatin 
n = 170
Any adverse event 67 (20) 37 (21.8)
Serious adverse events 4 (1.2) 5 (2.9)
Led to death 1 (0.3) 0 (0)
Led to treatment 
discontinuation
24 (7.2) 7 (4.1)
Most common AEs
Nausea 13 (3.9) 6 (3.5)
Myalgia 10 (3.0) 1 (0.6)
Diarrhea 5 (1.5) 2 (1.2)
Headache 4 (1.2) 2 (1.2)
AMI 4 (1.2) 0 (0)
Abbreviations: AE, adverse events; AMI, acute myocardial infarction.Vascular Health and Risk Management 2008:4(6) 1414
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Limitations
Because of the open-label design of the study, patient 
reporting of AEs could have been affected by their awareness 
of drug treatment or expectations from previous experiences 
with statins. However, the number and nature of AEs were 
generally consistent with those observed in previous trials. 
At the same time, the 12-week study period was long enough 
to demonstrate the LDL-C reducing effect and possible AEs 
of statin therapy (Brown et al 2002; Olsson et al 2002).
In conclusion, in the DISCOVERY-Beta Study in patients 
with primary hypercholesterolemia and high risk of CVD 
in clinical practice, greater reduction in LDL-C and TC 
levels was achieved with rosuvastatin 10 mg compared with 
simvastatin 20 mg, with more patients achieving the 1998 
EAS and the 2003 EAS LDL-C and TC goals. Both statin 
treatments were well tolerated.
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Appendix
The following centers and investigators (all in Estonia) 
participated in the trial.
North-Estonia Regional Hospital, Tallinn   – T. Laks 
(National Co-ordinator), R Vettus, M. Zemtsovski, L. Anton, 
Ü. Planken, L. Kalinina, A. Leht, H. Tupits, P. Rudenko, 
A. Ambos; Mustamäe Outpatient Clinic, Tallinn – A. Kreis 
(Principal Investigator, PI), M. Leiner, K. Valkenklau, 
A. Kund, T. Kivimäe, M. Mäemets, E. Gustavson, 
E. Nukk, T. Simm; Sütiste Centre, Tallinn – Ü. Kaasik (PI), 
K. Kender, A. Rosenthal, T. Jürgenson; West-Tallinn Central 
Hospital, Tallinn – I. Lapidus (PI), H. Kaljusaar, L. Aug, 
A. Bljumovitš, O. Kolbassova, S. Masik; East-Tallinn 
Central Hospital – A. Reinold (PI), A. Kork, M. Kadarik, 
M. Reimand, O. Taaler; Pelgulinna Outpatient Clinic, 
Tallinn – P. Laan (PI), T. Nurmoja, S. Reinmets; Lasnamäe 
Health Centre, Tallinn – I. Loogna (PI), L. Meledina (PI), 
N. Pantelejeva, S. Ehiloo, J. Ivanov, R. Aivazjan, I. Dmitrieva; 
Nõmme Family Doctors’ Centre, Tallinn – P. Pärnakivi (PI), 
E. Ehatamm, M. Alba, K. Kuningas, J. Miller, P. Tammist, 
M. Doroš, T. Oruaas, E. Merilind, K. Merilind, R. Raamat; 
Keila Family Physicians Centre – M. Võsa (PI); Saue Family 
Doctors’ Centre - A. Mäeorg (PI), A. Soomets; Saku Health 
Centre – M. Petersen (PI), M. Stern; Kuressaare Health 
Centre – V. Nemvalts (PI), S. Väli, E. Nurmekivi, T. Tarkin; 
Narva Outpatient Clinic – O. Averina (PI); Rakvere 
Centre – L. Slobodtshikova (PI), K. Veidrik, A. Kullerkupp; 
Tartu Puusepa Centre - Ü. Roostalu (PI), M. Treial, 
L. Koppel; Gildi Outpatient Clinic, Tartu – H. Loogus (PI), 
M. Plaks, L. Pilv, S. Saarniit, M. Nirk, M. Peda, L. Pullerits; 
Elva Family Physician – T. Laasik (PI); Viljandi Outpatient 
Clinic – E. Keba (PI).